Summary
Biogen Inc. reported its first quarter 2023 financial results, showing a decrease in total revenue to $2,463.0 million from $2,531.8 million in the prior year, primarily driven by a significant decline in product revenue, down 14.7% year-over-year. This decline was largely attributable to increased generic competition for TECFIDERA and continued pressure on its Multiple Sclerosis (MS) portfolio, as well as a decrease in Spinal Muscular Atrophy (SMA) revenue. Despite the revenue challenges, diluted earnings per share (EPS) saw a notable increase of 29.6% to $2.67, driven by cost-reduction measures and a favorable tax rate. The company also highlighted progress in its Alzheimer's disease treatment, LEQEMBI, which received accelerated approval in January 2023 and is now commercially available, contributing $18.9 million in revenue during the quarter as a profit share. Key financial developments include a decrease in total costs and expenses by 7.3%, largely due to lower cost of sales, partly from a significant inventory write-off in the prior year's comparable quarter. Biogen generated $455.3 million in operating cash flow and maintained a strong liquidity position with approximately $6.0 billion in cash, cash equivalents, and marketable securities. The company continues to invest in its pipeline, with R&D expenses increasing by 3.4%, particularly in areas like Alzheimer's and neurology. Recent developments include the FDA approval of QALSODY for ALS and continued regulatory review for LEQEMBI in multiple geographies. Biogen is also exploring strategic options for its biosimilars business.
Financial Highlights
49 data points| Revenue | $2.46B |
| Cost of Revenue | $662.80M |
| Gross Profit | $1.80B |
| SG&A Expenses | $605.00M |
| Operating Expenses | $2.02B |
| Interest Expense | $62.50M |
| Net Income | $387.90M |
| EPS (Basic) | $2.69 |
| EPS (Diluted) | $2.67 |
| Shares Outstanding (Basic) | 144.40M |
| Shares Outstanding (Diluted) | 145.20M |
Key Highlights
- 1Total revenue decreased by 2.7% to $2,463.0 million, driven by a 14.7% drop in product revenue to $1,763.3 million, primarily due to generic competition for TECFIDERA and ongoing MS portfolio challenges.
- 2Diluted earnings per share (EPS) increased significantly by 29.6% to $2.67, reflecting improved operational efficiency and cost management.
- 3LEQEMBI, an Alzheimer's treatment, received accelerated FDA approval in January 2023 and contributed $18.9 million as a profit share in its first quarter of commercialization.
- 4Operating cash flow strengthened, reaching $455.3 million, a 181.4% increase year-over-year.
- 5Total costs and expenses decreased by 7.3% to $2,024.7 million, benefiting from lower cost of sales and effective cost-reduction measures.
- 6Biogen generated $455.3 million in net cash flow from operating activities.
- 7The company is exploring strategic options for its biosimilars business, which saw a slight revenue decrease of 1.0%.